Zomedica Corp. (NYSEAMERICAN:ZOM – Get Free Report) CEO Larry C. Heaton II purchased 100,000 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was purchased at an average price of $0.12 per share, for a total transaction of $12,000.00. Following the completion of the purchase, the chief executive officer now owns 400,000 shares in the company, valued at $48,000. The transaction was disclosed in a filing with the SEC, which is available at this link.
Zomedica Stock Performance
ZOM stock opened at $0.13 on Friday. The stock has a market capitalization of $124.26 million, a price-to-earnings ratio of -3.17 and a beta of 1.03. Zomedica Corp. has a fifty-two week low of $0.12 and a fifty-two week high of $0.23.
Institutional Investors Weigh In On Zomedica
Several hedge funds and other institutional investors have recently made changes to their positions in ZOM. Price T Rowe Associates Inc. MD increased its stake in shares of Zomedica by 41.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 948,300 shares of the company’s stock worth $139,000 after purchasing an additional 276,100 shares in the last quarter. Frazier Financial Advisors LLC purchased a new stake in Zomedica in the fourth quarter worth about $50,000. Finally, Virtu Financial LLC raised its stake in shares of Zomedica by 1,585.0% in the first quarter. Virtu Financial LLC now owns 168,773 shares of the company’s stock worth $25,000 after buying an additional 158,757 shares during the period. Hedge funds and other institutional investors own 8.95% of the company’s stock.
About Zomedica
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
Further Reading
- Five stocks we like better than Zomedica
- Ride Out The Recession With These Dividend Kings
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.
